The startup operates a clinical trials facility that specializes in the cryopreservation of immune cells prior to chemotherapy, enabling patients to bank their cells for future participation in cell therapy trials at no cost. This service addresses the challenge of limited access to personalized cell therapies by ensuring that patients have preserved immune cells available for advanced treatment options.
Funding
$270K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Critically ill cancer patients often face limited access to advanced cell therapies like CAR-T, and even when accessible, the therapies may not be as effective due to disease progression and prior treatments. The current system often puts patients at a disadvantage, with limited options as standard treatments fail.
Solution
Achieve Clinics operates a network of clinical sites that facilitates access to personalized cell therapies by banking patients' immune cells early in their treatment journey, at no cost to the patient. The company collects, processes, and cryopreserves immune cells via apheresis, ensuring they are available for future cell therapy trials. Achieve Clinics connects patients with relevant clinical-stage cell therapy companies and provides access to banked cells, streamlining enrollment and potentially improving outcomes. The company also offers cell therapy developers access to a HIPAA-compliant, de-identified registry of banked patients and can provide surplus cells for research and development purposes, supporting the advancement of immuno-oncology.
Target Audience
The primary target audience includes cancer patients seeking access to cell therapies, oncologists looking to expand treatment options for their patients, and cell therapy developers seeking to accelerate trial enrollment and improve outcomes.
Features
- Immune cell collection and cryopreservation via apheresis at no cost to patients.
- Storage of cells in a manner suitable for future cell therapy manufacturing.
- Facilitation of connections between patients and cell therapy developers for clinical trial enrollment.
- HIPAA-compliant, de-identified patient registry for cell therapy developers.
- Option for patients to donate surplus cells to the research community.
- Support for various cancer types, including B-ALL, colorectal, gastric, and neuroendocrine cancers.
- Decentralized clinical site network to accommodate patients in multiple cities.